Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain

Nanjing Delova Biotech Co., Ltd. ("Delova") today announced positive results from two pivotal Phase 3 clinical trials ...